Track topics on Twitter Track topics that are important to you
Teva Pharmaceutical Industries' twice-daily tablet Vantrela ER, or hydrocodone bitartrate, has been endorsed for approval by -More-
JERUSALEM--(BUSINESS WIRE)--Jun. 7, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety ...
FDA's Anesthetic and Analgesic Drug Products committee and Drug Safety and Risk Management advisory committee voted 14-3 to recommend approval of Vantrela ER hydrocodone bitartrate (CEP-33237) from Te...
How have prescribing patterns for hydrocodone/acetaminophen among veterans changed in recent years? Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health
The switch of hydrocodone-containing combination drugs from Schedule III to the more restrictive Schedule II in October 2014 significantly reduced the number of prescriptions filled for these drugs, a...
An extension study shows that patients receiving an investigational abuse-deterrent hydrocodone (Vantrela ER) maintained pain relief for 6 months and that the drug was still safe. Medscape Medical N...
Collegium Pharmaceutical has unveiled positive topline results from a clinical study evaluating Hydrocodone DETERx as a second product candidate using its proprietary DETERx drug delivery technology p...
Hydrocodone bitartrate extended-release (Hysingla(®) ER; referred to hereafter as hydrocodone ER) was the first single-entity hydrocodone formulation recognized by the US FDA as having abuse-deterren...
A once-daily, extended-release hydrocodone bitartrate tablet with abuse-deterrent properties (Hysingla ER [HYD]) is available for the treatment of chronic pain in appropriate patients. This study e...
The purpose of this study was to evaluate the pharmacokinetics (PK) and 24-hour analgesic effectiveness of once-daily, single-entity, extended-release hydrocodone (HYD) with abuse-deterrent properties...
Immediate-release (IR) hydrocodone is the most widely prescribed opioid in the United States; however, little is known about the utilization patterns and duration of opioid use among patients prescrib...
The U.S. Drug Enforcement Administration (DEA) rescheduled hydrocodone combination products (HCPs) in an attempt to mitigate the prescription opioid epidemic. Many in the medical and pharmacy communit...